Cargando…

Plasma levels of BDNF and EGF are reduced in acute stroke patients

Stroke affects almost 14 million people worldwide each year. It is the second leading cause of death and a major cause of acquired disability. The degree of initial impairment in cognitive and motor functions greatly affects the recovery, but idiosyncratic factors also contribute. These are largely...

Descripción completa

Detalles Bibliográficos
Autores principales: Øverberg, Linda Thøring, Lugg, Elise Fritsch, Gaarder, Mona, Langhammer, Birgitta, Thommessen, Bente, Rønning, Ole Morten, Morland, Cecilie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218156/
https://www.ncbi.nlm.nih.gov/pubmed/35756121
http://dx.doi.org/10.1016/j.heliyon.2022.e09661
_version_ 1784731816969633792
author Øverberg, Linda Thøring
Lugg, Elise Fritsch
Gaarder, Mona
Langhammer, Birgitta
Thommessen, Bente
Rønning, Ole Morten
Morland, Cecilie
author_facet Øverberg, Linda Thøring
Lugg, Elise Fritsch
Gaarder, Mona
Langhammer, Birgitta
Thommessen, Bente
Rønning, Ole Morten
Morland, Cecilie
author_sort Øverberg, Linda Thøring
collection PubMed
description Stroke affects almost 14 million people worldwide each year. It is the second leading cause of death and a major cause of acquired disability. The degree of initial impairment in cognitive and motor functions greatly affects the recovery, but idiosyncratic factors also contribute. These are largely unidentified, which contributes to making accurate prediction of recovery challenging. Release of soluble regulators of neurotoxicity, neuroprotection and repair are presumably essential. Here we measured plasma levels of known regulators of neuroprotection and repair in patients with mild acute ischemic stroke and compared them to the plasma levels in healthy age and gender matched controls. We found that the levels of BDNF and EGF were substantially lower in stroke patients than in healthy controls, while the levels of bFGF and irisin did not differ between the groups. The lower levels of growth factors highlight that during the acute phase of stroke, there is a mismatch between the need for neuroprotection and repair, and the brain's ability to induce these processes. Large individual differences in growth factor levels were seen among the stroke patients, but whether these can be used as predictors of long-term prognosis remains to be investigated.
format Online
Article
Text
id pubmed-9218156
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92181562022-06-24 Plasma levels of BDNF and EGF are reduced in acute stroke patients Øverberg, Linda Thøring Lugg, Elise Fritsch Gaarder, Mona Langhammer, Birgitta Thommessen, Bente Rønning, Ole Morten Morland, Cecilie Heliyon Research Article Stroke affects almost 14 million people worldwide each year. It is the second leading cause of death and a major cause of acquired disability. The degree of initial impairment in cognitive and motor functions greatly affects the recovery, but idiosyncratic factors also contribute. These are largely unidentified, which contributes to making accurate prediction of recovery challenging. Release of soluble regulators of neurotoxicity, neuroprotection and repair are presumably essential. Here we measured plasma levels of known regulators of neuroprotection and repair in patients with mild acute ischemic stroke and compared them to the plasma levels in healthy age and gender matched controls. We found that the levels of BDNF and EGF were substantially lower in stroke patients than in healthy controls, while the levels of bFGF and irisin did not differ between the groups. The lower levels of growth factors highlight that during the acute phase of stroke, there is a mismatch between the need for neuroprotection and repair, and the brain's ability to induce these processes. Large individual differences in growth factor levels were seen among the stroke patients, but whether these can be used as predictors of long-term prognosis remains to be investigated. Elsevier 2022-06-10 /pmc/articles/PMC9218156/ /pubmed/35756121 http://dx.doi.org/10.1016/j.heliyon.2022.e09661 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Øverberg, Linda Thøring
Lugg, Elise Fritsch
Gaarder, Mona
Langhammer, Birgitta
Thommessen, Bente
Rønning, Ole Morten
Morland, Cecilie
Plasma levels of BDNF and EGF are reduced in acute stroke patients
title Plasma levels of BDNF and EGF are reduced in acute stroke patients
title_full Plasma levels of BDNF and EGF are reduced in acute stroke patients
title_fullStr Plasma levels of BDNF and EGF are reduced in acute stroke patients
title_full_unstemmed Plasma levels of BDNF and EGF are reduced in acute stroke patients
title_short Plasma levels of BDNF and EGF are reduced in acute stroke patients
title_sort plasma levels of bdnf and egf are reduced in acute stroke patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218156/
https://www.ncbi.nlm.nih.gov/pubmed/35756121
http://dx.doi.org/10.1016/j.heliyon.2022.e09661
work_keys_str_mv AT øverberglindathøring plasmalevelsofbdnfandegfarereducedinacutestrokepatients
AT luggelisefritsch plasmalevelsofbdnfandegfarereducedinacutestrokepatients
AT gaardermona plasmalevelsofbdnfandegfarereducedinacutestrokepatients
AT langhammerbirgitta plasmalevelsofbdnfandegfarereducedinacutestrokepatients
AT thommessenbente plasmalevelsofbdnfandegfarereducedinacutestrokepatients
AT rønningolemorten plasmalevelsofbdnfandegfarereducedinacutestrokepatients
AT morlandcecilie plasmalevelsofbdnfandegfarereducedinacutestrokepatients